MenQuadfi was developed throughA novel serogroup-specific design1,2

OUR MULTISTEP APPROACH:

1 in white-ruled box

Tetanus toxoid was identified as an alternative to the protein carrier used in other US-licensed MenACWY* vaccines1,2

2 in white-ruled box

Individual conjugate structures were evaluated for each serogroup (A, C, W, and Y)1

3 in white-ruled box

Chemical and structural features for each serogroup achieved the demonstrated immune response1

WATCH A VIDEO ABOUT OUR NOVEL DESIGN

Committed to the fight against meningococcal disease

In the US, Sanofi has been a leader in this fight for more than 40 years3-6

TIMELINE 1978 First & only bivalent (A,C) meningococcal vaccine; 1981 First & only quadrivalent meningococcal polysaccharide vaccine; 2005 First & only quadrivalent meningococcal conjugate vaccine liquid formulation; 2014 MenACWY vaccine licensed for 2nd dose; 2020
 MenQuadfi, protect expanded age group of individuals 2 years and older TIMELINE 1978 First & only bivalent (A,C) meningococcal vaccine; 1981 First & only quadrivalent meningococcal polysaccharide vaccine; 2005 First & only quadrivalent meningococcal conjugate vaccine liquid formulation; 2014 MenACWY vaccine licensed for 2nd dose; 2020
 MenQuadfi, protect expanded age group of individuals 2 years and older

SANOFI partners with public health stakeholders to help improve immunization rates and access to vaccines, with a heritage of innovation and partnership that will continue into the future.

IMPORTANT SAFETY INFORMATION

MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including invasive disease caused by serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in place to prevent falling and injury and to manage syncope.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age and older include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

* MenACWY = N meningitidis serogroups A, C, W, and Y.

REFERENCES:

  1. MenQuadfi [Prescribing Information]. Sanofi Pasteur Inc.
  2. About meningococcal vaccines. Centers for Disease Control and Prevention. October 12, 2021. Accessed July 13, 2022. https://www.cdc.gov/vaccines/vpd/mening/hcp/about-vaccine.html
  3. FDA approves MenQuadfi™, the latest innovation in meningococcal (MenACWY) vaccination. Press release. Sanofi; April 24, 2020. Accessed January 11, 2022. https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-24-07-00-00
  4. Vaccine timeline. Immunization Action Coalition. Updated October 21, 2021. Accessed December 15, 2021. https://www.immunize.org/timeline
  5. Menactra [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.
  6. FDA approves use of Menactra® vaccine for booster immunization against potentially deadly disease. Press release. Sanofi; September 8, 2014. Accessed January 11, 2022. https://www.news.sanofi.us/press-releases?item=137127

Back to the top